| P2093 | author name string | Athan Kuliopulos | |
| | Lidija Covic | |
| P2860 | cites work | ALEX1, a novel tumor suppressor gene, inhibits gastric cancer metastasis via the PAR-1/Rho GTPase signaling pathway | Q87595942 |
| | HMGA2 and Smads co-regulate SNAIL1 expression during induction of epithelial-to-mesenchymal transition | Q24318681 |
| | Thrombin receptor overexpression in malignant and physiological invasion processes | Q24323035 |
| | Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation | Q24337851 |
| | Activation and inhibition of G protein-coupled receptors by cell-penetrating membrane-tethered peptides | Q24530304 |
| | Cell-surface receptors transactivation mediated by g protein-coupled receptors | Q26827583 |
| | G-protein-coupled receptors signaling pathways in new antiplatelet drug development | Q26864951 |
| | Molecular mechanisms of epithelial-mesenchymal transition | Q27013743 |
| | Turning receptors on and off with intracellular pepducins: new insights into G-protein-coupled receptor drug development | Q27024397 |
| | High-resolution crystal structure of human protease-activated receptor 1 | Q27675402 |
| | The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells | Q28143877 |
| | Role of the PAR4 thrombin receptor in stabilizing platelet-platelet aggregates as revealed by a patient with Hermansky-Pudlak syndrome | Q28217333 |
| | Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? | Q29547559 |
| | Matrix metalloproteinases and the regulation of tissue remodelling | Q29618747 |
| | Matrix metalloproteinases: regulators of the tumor microenvironment | Q29619858 |
| | Novel oral anticoagulants in acute coronary syndrome | Q30421410 |
| | The thrombin receptor, PAR-1, causes transformation by activation of Rho-mediated signaling pathways | Q30989694 |
| | Presentation and management of docetaxel-related adverse effects in patients with breast cancer | Q33698286 |
| | Discovery of a CXCR4 agonist pepducin that mobilizes bone marrow hematopoietic cells. | Q33765419 |
| | The Ras-related protein, Rap1A, mediates thrombin-stimulated, integrin-dependent glioblastoma cell proliferation and tumor growth | Q33792985 |
| | Matrix metalloproteinase 1 and circulating tumor cells in early breast cancer | Q33839166 |
| | Persistent transactivation of EGFR and ErbB2/HER2 by protease-activated receptor-1 promotes breast carcinoma cell invasion | Q33870552 |
| | FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer | Q34004891 |
| | Identification of a metalloprotease-chemokine signaling system in the ovarian cancer microenvironment: implications for antiangiogenic therapy | Q34048965 |
| | International Union of Pharmacology. XXVIII. Proteinase-activated receptors | Q34130822 |
| | Thrombin-receptor antagonist vorapaxar in acute coronary syndromes | Q34231934 |
| | Vorapaxar in the secondary prevention of atherothrombotic events | Q34263311 |
| | Blocking receptors on the inside: pepducin-based intervention of PAR signaling and thrombosis | Q34275527 |
| | Suppression of arterial thrombosis without affecting hemostatic parameters with a cell-penetrating PAR1 pepducin | Q34282119 |
| | Role of the PAR1 receptor 8th helix in signaling: the 7-8-1 receptor activation mechanism. | Q51304532 |
| | Noncanonical Matrix Metalloprotease 1-Protease-Activated Receptor 1 Signaling Drives Progression of Atherosclerosis. | Q52721277 |
| | MMP13 is potentially a new tumor marker for breast cancer diagnosis. | Q54463440 |
| | G protein-coupled receptor modulation with pepducins: moving closer to the clinic | Q56648575 |
| | Plasmin Desensitization of the PAR1 Thrombin Receptor: Kinetics, Sites of Truncation, and Implications for Thrombolytic Therapy† | Q58011108 |
| | Structural basis for thrombin activation of a protease-activated receptor: inhibition of intramolecular liganding | Q79339234 |
| | Reversing systemic inflammatory response syndrome with chemokine receptor pepducins | Q81725616 |
| | Atopaxar and its effects on markers of platelet activation and inflammation: results from the LANCELOT CAD program | Q84267561 |
| | Α-arrestins - new players in Notch and GPCR signaling pathways in mammals | Q87572745 |
| | Tumor progression locus 2 mediates signal-induced increases in cytoplasmic calcium and cell migration. | Q39484501 |
| | Tumor-derived Cyr61(CCN1) promotes stromal matrix metalloproteinase-1 production and protease-activated receptor 1-dependent migration of breast cancer cells | Q40309830 |
| | Pepducins and Other Lipidated Peptides as Mechanistic Probes and Therapeutics | Q40405065 |
| | PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. | Q40459317 |
| | Signaling from protease-activated receptor-1 inhibits migration and invasion of breast cancer cells | Q40789355 |
| | Cell-type specific regulation of human interstitial collagenase-1 gene expression by interleukin-1 beta (IL-1 beta) in human fibroblasts and BC-8701 breast cancer cells | Q41092404 |
| | Platelet matrix metalloprotease-1 mediates thrombogenesis by activating PAR1 at a cryptic ligand site | Q42177034 |
| | β-adrenergic receptor stimulation transactivates protease-activated receptor 1 via matrix metalloproteinase 13 in cardiac cells. | Q42219763 |
| | Irreversible platelet activation requires protease-activated receptor 1-mediated signaling to phosphatidylinositol phosphates | Q42265142 |
| | Dysregulated protease activated receptor 1 (PAR1) promotes metastatic phenotype in breast cancer through HMGA2. | Q42479614 |
| | Oncogenic transformation induces tumor angiogenesis: a role for PAR1 activation | Q42805836 |
| | Insider access: pepducin symposium explores a new approach to GPCR modulation | Q43238652 |
| | Tumor cell invasion is promoted by activation of protease activated receptor-1 in cooperation with the alpha vbeta 5 integrin | Q43559301 |
| | Prognostic role of protease-activated receptors 1 and 4 in resected stage IB non-small-cell lung cancer | Q43644512 |
| | Magnetic Fields and Reactive Oxygen Species | Q46277884 |
| | Polymorphisms of the promoter regions of matrix metalloproteinases genes MMP-1 and MMP-9 in breast cancer | Q46788870 |
| | Doxycycline inhibits breast cancer EMT and metastasis through PAR-1/NF-κB/miR-17/E-cadherin pathway | Q47141937 |
| | TGF-β induced PAR-1 expression promotes tumor progression and osteoclast differentiation in giant cell tumor of bone. | Q48188314 |
| | -The a-arrestin ARRDC3 suppresses breast carcinoma invasion by regulating G protein-coupled receptor lysosomal sorting and signaling | Q49954335 |
| | Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial | Q50204823 |
| | Matrix metalloprotease 1a deficiency suppresses tumor growth and angiogenesis. | Q34457039 |
| | Mouse matrix metalloprotease-1a (Mmp1a) gives new insight into MMP function | Q34488791 |
| | Chemokine and cytokine processing by matrix metalloproteinases and its effect on leukocyte migration and inflammation | Q34665150 |
| | 'Role reversal' for the receptor PAR1 in sepsis-induced vascular damage | Q34686193 |
| | Interdicting protease-activated receptor-2-driven inflammation with cell-penetrating pepducins | Q35002854 |
| | Targeting protease-activated receptor-1 with cell-penetrating pepducins in lung cancer | Q35070124 |
| | Histone deacetylase inhibition is associated with transcriptional repression of the Hmga2 gene | Q35107914 |
| | Host and tumor derived MMP13 regulate extravasation and establishment of colorectal metastases in the liver | Q35154433 |
| | MUC1-C Induces the LIN28B→LET-7→HMGA2 Axis to Regulate Self-Renewal in NSCLC | Q35204592 |
| | Targeting CXCR4 with cell-penetrating pepducins in lymphoma and lymphocytic leukemia | Q35776992 |
| | Allosteric Activation of a G Protein-coupled Receptor with Cell-penetrating Receptor Mimetics | Q35860717 |
| | Endothelial Angiogenesis and Barrier Function in Response to Thrombin Require Ca2+ Influx through the Na+/Ca2+ Exchanger | Q35883805 |
| | A matrix metalloprotease-PAR1 system regulates vascular integrity, systemic inflammation and death in sepsis. | Q36088900 |
| | Matrix metalloprotease-1a promotes tumorigenesis and metastasis | Q36097959 |
| | PH motifs in PAR1&2 endow breast cancer growth | Q36357012 |
| | Biased agonism of protease-activated receptor 1 by activated protein C caused by noncanonical cleavage at Arg46. | Q36509665 |
| | Matrix metalloproteases and PAR1 activation | Q36542806 |
| | Expression cloning of oncogenes by retroviral transfer of cDNA libraries | Q36566564 |
| | Colon Cancer Growth and Dissemination Relies upon Thrombin, Stromal PAR-1, and Fibrinogen | Q36732743 |
| | Cell-Penetrating Pepducin Therapy Targeting PAR1 in Subjects With Coronary Artery Disease | Q36813106 |
| | Twist-mediated Epithelial-mesenchymal Transition Promotes Breast Tumor Cell Invasion via Inhibition of Hippo Pathway | Q36814799 |
| | Matrix metalloproteinase Mmp-1a is dispensable for normal growth and fertility in mice and promotes lung cancer progression by modulating inflammatory responses | Q36850412 |
| | Noncanonical matrix metalloprotease-1-protease-activated receptor-1 signaling triggers vascular smooth muscle cell dedifferentiation and arterial stenosis | Q37095396 |
| | Tumor MMP-1 activates endothelial PAR1 to facilitate vascular intravasation and metastatic dissemination | Q37125854 |
| | PAR1 is selectively over expressed in high grade breast cancer patients: a cohort study | Q37246397 |
| | Blockade of PAR1 signaling with cell-penetrating pepducins inhibits Akt survival pathways in breast cancer cells and suppresses tumor survival and metastasis | Q37322052 |
| | Targeting a metalloprotease-PAR1 signaling system with cell-penetrating pepducins inhibits angiogenesis, ascites, and progression of ovarian cancer | Q37326414 |
| | Biased signaling of protease-activated receptors | Q38214613 |
| | IMP-3 promotes migration and invasion of melanoma cells by modulating the expression of HMGA2 and predicts poor prognosis in melanoma | Q38303159 |
| | Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes: the lessons from antagonizing the cellular effects of Thrombin–Acute Coronary Syndromes Trial | Q38492131 |
| | Randomized trial of atopaxar in the treatment of patients with coronary artery disease: the lessons from antagonizing the cellular effect of Thrombin–Coronary Artery Disease Trial | Q38492142 |
| | The Role of Na+/Ca2+ Exchanger 1 in Maintaining Ductus Arteriosus Patency | Q38602981 |
| | HMGA2 functions as a competing endogenous RNA to promote lung cancer progression. | Q39048956 |
| | Direct interaction between an allosteric agonist pepducin and the chemokine receptor CXCR4. | Q39476674 |
| P275 | copyright license | Creative Commons Attribution | Q6905323 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 8 | |
| P921 | main subject | ovarian cancer | Q172341 |
| | ovarian neoplasm | Q11793790 |
| | lung neoplasm | Q15124212 |
| | breast neoplasm | Q23929670 |
| P577 | publication date | 2018-07-31 | |
| P1433 | published in | International Journal of Molecular Sciences | Q3153277 |
| P1476 | title | Protease-Activated Receptor 1 as Therapeutic Target in Breast, Lung, and Ovarian Cancer: Pepducin Approach | |
| P478 | volume | 19 | |